Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer.
Alkhatib H, Conage-Pough J, Roy Chowdhury S, Shian D, Zaid D, Rubinstein AM, Sonnenblick A, Peretz-Yablonsky T, Granit A, Carmon E, Kohale IN, Boughey JC, Goetz MP, Wang L, White FM, Kravchenko-Balasha N.
Alkhatib H, et al.
Mol Cancer. 2024 Jan 16;23(1):17. doi: 10.1186/s12943-023-01921-9.
Mol Cancer. 2024.
PMID: 38229082
Free PMC article.